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INTRODUCTION
The "Fetal Basis of Adult Disease" or Barker Hypothesis is relevant to a number of chronic diseases in humans including diabetes, asthma, cardiovascular disease, and cancer as well as neurological and behavior toxicities [1] [2] [3] [4] . With respect to cancer, a number of epidemiology studies have documented that exposure of pregnant women to environmental carcinogens such as cigarette smoke enhances the risk for the offspring of developing a number of cancers [5] [6] [7] . Animal models have documented that a number of chemicals are transplacental carcinogens including the tobacco specific nitrosamine NNK, the cooked meat mutagen PhIP (2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine), benzene, arsenic, phenytoin, drugs targeting HIV and polycyclic aromatic hydrocarbons (PAHs) [8] [9] [10] [11] [12] [13] [14] [15] [16] . PAHs have been documented to be bioavailable to the fetus and to generate DNA damage [17] [18] [19] [20] [21] [22] [23] . Dibenzo[def,p]chrysene (DBC) is a potent environmental PAH in animal models of carcinogenesis and has recently been reclassified by the International Agency for Research on Cancer (IARC) from possible carcinogenic (2B) to probably carcinogenic in humans (2A) [24] . Our laboratory has demonstrated that exposure of pregnant mice (C57B6129F1 dams bred to 129 males) to a single dose of DBC (15 mg/kg by gavage) during late pregnancy was carcinogenic to the offspring [16] . Over half the offspring had to be euthanized due to an aggressive T-cell lymphoblastic lymphoma that invaded almost every organ. The surviving mice at 10 months had a 100% incidence of pulmonary tumors (multiplicity of about 15) and approximately 70% of the males (and almost no females) had liver lesions (primarily precancerous lesions and adenomas) [16] . Subsequent studies with 4 cyp1b1 knockout mice demonstrated that fetal Cyp1b1 was required for development of the T-cell lymphoma [25] . Cross-fostering studies further demonstrated that the 2-3 day in utero exposure to DBC resulted in much higher lymphoma-associated mortality than exposure to residual DBC in the breast milk over the 3 weeks of nursing [26] .
Developmental expression of CYPs in the 1 family is important in the transplacental toxicities of PAHs [27] . Studies with expressed mouse and human CYPs have found that CYP1A1 and CYP1B1 are effective in the bioactivation of PAHs to mutagenic and carcinogenic metabolites, primarily diol-epoxides.
For example, Histopathology. At 10 months of age surviving mice were euthanized by CO 2 asphyxiation, followed by cervical dislocation, and a number of tissues (thymus, lung, liver, spleen, heart, kidney, testis, ovary, uterus, colon, skin, and any (abnormal) lymph nodes) examined first by gross necropsy and then fixed in 10% formalin. Fixed tissues were routinely processed to paraffin blocks, and hematoxylin and eosin-stained sections were analyzed by a board-certified histopathologist as previously described [16] .
Sample preparation for liquid scintillation [ 14 C]-DBC analysis. Fetal tissues including lung, liver, GI tract (stomach through colon with contents) were pooled by tissue type within a litter and solubilized directly as described previously [33] . Maternal plasma, spleen and lung or homogenized portions of liver, GI tract (with contents), placenta, and kidney, were solubilized accordingly. Feces required extended solubilization time and bleach to remove color. Samples were then clarified with 1:5 H 2 O 2 : 2-propanol, treated with glacial acetic acid to remove chemiluminescence and stored overnight in the dark before measuring radioactivity by liquid scintillation. (n=4 dams/litters sacrificed per time point) followed by trend and/or other contrasts. For the cross-fostered study there were n=3 pairs, so that the data are shown for each cross-foster litter pair and the by-tissue paired t-tests,comparing the exposure routes, had low power (2 denominator degrees of freedom and considerable residual variation).
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Maternal and Fetal Toxicity: Previous studies, utilizing this same cross of mouse strains and dosing with DBC on GD 17, did not result in any maternal or fetal toxicities as evidenced by the lack of an impact on the sex ratio (1.20 and 1.09, respectively), litter size (7.8 and 7.1) or birth weight [16] . In the present study there was no treatmentrelated effect on litter size or offspring gender ( Table 1) . Treatment of dams with multiple doses of DBC did not result in smaller pups at birth but there was a significant difference with respect to body weight of the pups upon weaning (11.8 g versus 9.6 g, p< 0.0001).
DBC Transplacental Carcinogenesis: The greatest difference in tumor response in the offspring from in utero exposure following treatment of dams with DBC at 4 doses of 3.75 mg/kg (maternal body weight) at GDs 5, 9, 13 and 17, compared to a single dose of 15 mg/kg at GD 17, was a total lack of mortality due to an aggressive T-cell lymphoblastic lymphoma. This lymphoma appears from ages 3-6 months much like what is observed in Tp53 (-/-) mice on the same genetic background [34] .
Following termination of the study, when offspring were 10 months of age, a marked difference in target organ response was observed between treatment regimes.
The incidence of lung tumors in all our previous studies employing the single high dose was 100% and the average lung tumor multiplicity was 13-15 (tumors/tumor-bearing mouse) [16, 25, 26, [35] [36] [37] . When a smaller DBC dose is administered over all trimesters, the lung tumor incidence was reduced to 80% (data not shown) and the multiplicity significantly reduced to 2.6 ± 0.4 (p< 0.0001) (Figure 1, right panel) . Gestational age at exposure to ethylnitrosourea (ENU) markedly influences the multiplicity, size and morphology of lung tumors [38, 39] . The greatest period of susceptibility to transplacental ENU lung tumorigenesis appears to be around GD 16, possibly due to variable rates of clonal expansion in the developing tissue [39] , with lung morphogenesis beginning on GD 10 [40] . In addition to changes in cellular proliferation and differentiation throughout gestation, age-specific susceptibility to mutagenic transplacental carcinogens such as ENU or PAHs may be due to differences in expression of metabolic enzymes or in repair pathway activation. As treatments were administered in this study on GD 5, 9, 13, and 17, it is possible that this window of susceptibility and the lower individual doses were both factors in the reduced lung tumor multiplicity observed. The reduction in liver lesions was also striking. Previously, the single high dose resulted in a lesion (precancerous lesions and adenomas) incidence of 70% (almost exclusively in males) while the multiple low doses yielded only a 6.3%
incidence (data not shown).
In contrast to the reduced response in lymphoma, lung and liver tumors, a reduced the number of primordial follicles by over two thirds [41] . Interestingly, the ovarian toxicity also occurred following lactational exposure but the greatest impact was ovarian toxicity nor did we examine lactational exposure as a separate factor (pups were exposed to residual DBC from distribution to maternal breast during gestation).
The uteri of ovarian tumor-bearing mice were examined and all showed cystic endometrial hyperplasia, a fairly common finding in older mice but previously not seen to any great degree in 10 month-old offspring from the B6129F1 x 129 cross.
In male offspring, abnormally small testes were seen, a pathology not previously observed with the late gestation single DBC dose ( Figure 2B ). Histologically, these testes showed diffuse atrophy of seminiferous tubules, marked Leydig cell hyperplasia, and scattered granulomas. Igsajim et al., [42] found that exposure of mice on GD 14 to the high potency Ahr ligand TCDD resulted in an Ahr-dependent negative impact on prostate development. TCCD has been known to be a reproductive toxicant in mice and other rodents, reducing ano-genital distance and sperm viability later in life [43, 44] .
Leydig cell hyperplasia has been documented in male mice following transplacental exposure to estradiol and diethylstilbestrol [45, 46] . Evidence also exists in humans for maternal smoking similarly producing a negative impact on testicular development, possibly due in part to PAH exposure [47, 48] .
Our results suggest differential tissue susceptibility to DBC, depending on age of development at exposure. These findings are similar to studies with an environmental mixture of PAHs, cigarette smoke, that differentially affects cancer incidence and target shown to retain radioactivity much longer than other maternal organs [51] . When expressed as a ratio relative to plasma concentration, the following maternal tissues exhibited an approximately constant percent increase per hour (kidney, 23.6%; liver, 19.6%; lung, 9.9%, and placenta, 26.4%).
Compared to maternal plasma, fetal tissues exhibited 4-to 13-fold lower levels of Figure 3C ). For animals euthanized at 8 hours, maternal lung and liver levels were 8-and 16-fold higher, than the respective fetal tissue ( Figure 3A and 3C ).
The fetal tissue:plasma ratios did not increase over the first 6 hours nor did they differ between tissues, however at 8 hours this ratio increased dramatically as plasma levels dropped, with fetal GI tract:plasma significantly higher than other tissues.
The elimination of [ 14 C]-DBC in maternal urine and feces was also followed over the 2-8 hour time-course demonstrating that the great majority of [ 14 C]-DBC equivalents were eliminated in the feces as expected for an oral exposure ( Figure 3D ).
However, this study was not designed to characterize the pharmacokinetics of on the pharmacokinetics of DBC and its metabolites in blood, feces, urine, tissues, and fetuses (where applicable) from these mice. Such data will facilitate the continued development and refinement of a physiologically based pharmacokinetic model for DBC [52] that will ultimately be used to relate dose levels used in these mouse carcinogenicity studies to relevant human exposure scenarios.
In our previous studies on the transplacental carcinogenesis properties of DBC,
we performed a study with a cross-foster design [26] . We were somewhat surprised to see that the majority of the T-cell lymphoblastic lymphoma mortality was due to the short 2-3 day in utero exposure; pups exposed only through breast milk had little mortality. Lung tumor multiplicity at 10 months of age was also significantly higher in offspring only exposed in utero. We speculated that the difference may be that DBC, like other PAHs, had a relatively short half-life in the dam and by parturition, little DBC remained to partition into breast milk. It was outside the scope of this study to examine the residual DBC at the onset of lactational exposure or to measure partitioning of DBC into breast milk. When cross-fostered litters were matched according to exposed dam, we were unable to detect any significant difference in the concentration of transplacental model requires that we characterize DBC metabolites and DBC-covalent adducts in the various maternal and fetal tissues throughout gestation and lactation, and is now ongoing as described above.
DBC-DNA adducts in fetal lung, reported in one of our previous studies [35] , was similar to maternal lung. The major DNA adducts of DBC are derived from Cyp1-dependent epoxygenation, followed by hydrolysis to the trans-dihydrodiol (DBCD) which is epoxygenated a second time to 11,12-trans-dihydrodiol-13,14-epoxide (DBCDE, 4 possible enantiomers). These fjord region PAH diol-epoxides, in most animal models [53] [54] [55] , are more carcinogenic than the bay region BPDEs. Cyp1b1 (and human CYP1B1) are very efficient at carrying out both epoxygenations, followed by Cyp1a1 with a smaller contribution from Cyp1a2 [28, 29] .
The absolute requirement for Cyp1b1 expression in fetal thymus [25] for induction of T-cell lymphoma suggests that one or more of the key steps in the bioactivation of DBC occurs in the fetal compartment. Given the very high chemical reactivity of the most potent of the diol-epoxide metabolites, DBCDE, it is unlikely that it crosses the placenta and distributes to fetal thymus tissues without hydrolysis or reaction with nucleophiles.
In conclusion, we have demonstrated in this manuscript that the target tissue response for PAH-dependent transplacental carcinogenesis in this mouse model is dependent, to a large degree, on the stage of development during exposure. The high sensitivity to developing T-cell lymphoma when the dam is dosed on GD 17 is consistent with the developmental expression of Cyp1b1 (thymus expresses the highest 16 level of Cyp1b1 mRNA during late gestation in both mouse and human) [34, 56] . The log 2 ratio of SUM DBC (DBC or metabolite equivalents) from paired lactational/ in utero exposure litters (panel B) is generally greater than 1 (represented by the dotted horizontal line).
